Kisqali (ribociclib)

Description

Kisqali (ribociclib)

A targeted treatment for HR+/HER2− advanced or metastatic breast cancer

Kisqali is a prescription medicine used in combination with endocrine therapy to treat certain types of breast cancer in adults. It is developed by Novartis and belongs to a class of medicines called CDK4/6 inhibitors.

---

About Kisqali

Kisqali is designed for people diagnosed with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced or metastatic breast cancer.

It is used in combination with:

• An aromatase inhibitor (for postmenopausal patients), or
• Fulvestrant (in certain treatment settings)

Kisqali works alongside hormone therapy to help slow the progression of cancer.

---

How Kisqali Works

Cancer cells can grow and divide uncontrollably. Kisqali targets specific proteins called CDK4 and CDK6, which play a key role in cell cycle progression.

By inhibiting these proteins, Kisqali helps:

• Slow down cancer cell division
• Delay disease progression
• Enhance the effectiveness of endocrine (hormone) therapy

---

Who Kisqali Is For

Kisqali is prescribed for adult patients with:

• HR-positive breast cancer
• HER2-negative status
• Advanced or metastatic disease

Treatment decisions are made by an oncologist based on individual medical evaluation.

---

How to Take Kisqali

Kisqali is taken orally as tablets, usually:

• Once daily
• For 21 consecutive days followed by 7 days off (28-day cycle)
• In combination with prescribed hormone therapy

Patients should follow their doctor’s exact instructions regarding dosage and schedule.

---

Possible Side Effects

Like all cancer treatments, Kisqali may cause side effects. Some of the most commonly reported include:

• Low white blood cell counts (neutropenia)
• Nausea
• Fatigue
• Diarrhea or constipation
• Headache

More serious effects can occur in some patients, including liver changes or heart rhythm changes. Regular monitoring through blood tests and ECGs is often recommended by healthcare providers.

---

Monitoring During Treatment

Patients on Kisqali may require regular check-ups, including:

• Blood tests to monitor liver function and blood counts
• Heart monitoring (ECG)
• Routine clinical assessments

This helps ensure treatment safety and effectiveness.

---

Patient Support

Support programs may be available depending on your region, offering:

• Treatment guidance
• Adherence support
• Access and affordability assistance
• Educational resources for patients and caregivers

---

Important Information

Kisqali is a prescription medicine and should only be taken under the supervision of a qualified healthcare professional. It is not suitable for all patients and may interact with other medications.

Always consult your oncologist for personalized medical advice.